Boston Scientific upgraded at BofA/Merrill As previously reported, BofA/Merrill upgraded Boston Scientific to Buy from Neutral. The firm upgraded shares given increased confidence in the pipeline, opportunities to increase margin, valuation, and expectations the FDA will approve the LAA product this year. Price target raised to $16.
Boston Scientific announces CE Mark for MRI labeling for ICD, CRT-D systems Boston Scientific has received CE Mark on magnetic resonance imaging conditional labeling for the current family of EL and MINI implantable cardioverter defibrillator and the X4 cardiac resynchronization therapy defibrillator systems. This revised labeling ensures that future patients and those already implanted with these systems are able to undergo MRI scans if indicated.